



다양한 식도증상에 따른 접근법

Yang Won Min

Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Korea


Symptoms related to esophagus

- Dysphagia
 - Esophageal (transport)
 - Oropharyngeal (transfer)
- Heartburn
- Regurgitation
- Odynophagia
- Chest pain
- Globus
- Supraesophageal symptoms
 - Cough and hoarseness

Dysphagia

- Problems with the transit of food or liquid from the mouth to the stomach
- Common clinical problem in the elderly
 - Due to aging per se?

Factors associated with dysphagia in the elderly



Dysphagia in the elderly

- Aging alone causes mild esophageal motility abnormalities, which are rarely symptomatic.
- Should not be attributed to the normal aging
- Many diseases with the potential to provoke dysphagia show increasing prevalence with increasing age


Need for an **immediate evaluation** to define the exact cause and initiate appropriate therapy

4개월 간 GERD 치료, M/67



Two types of dysphagia

- Oropharyngeal dysphagia
(=transfer dysphagia)
- Esophageal dysphagia
(=transport dysphagia)



Oropharyngeal dysphagia

- Typical symptoms
 - Drooling, coughing, and gurgling upon eating
 - Nasal regurgitation of food or liquid
 - Very soon after the onset of eating
- Cervical location of the dysphagia?
 - Occasionally in esophageal dysphagia

Causes of oropharyngeal dysphagia

Anatomic

Zenker's
Diverticulum
Tumor
Enlarged Thyroid
Osteophyte
Head/Neck Surgery
Web
Abscess

Neurologic


Cerebrovascular
Accident
Post-Polio Syndrome
Radiation Injury
Parkinsonism
Head/Neck Surgery
Multiple Sclerosis
CNS tumor
Botulism
Supranuclear Palsy
Myotonic Dystrophy
Amyotrophic Lateral
Sclerosis

Muscular



Polymyositis
Myasthenia Gravis
Muscular dystrophy
Radiation Injury
Thyroid Disease
Head/Neck surgery

Zenker's diverticulum (=hypopharyngeal diverticulum)

- Usually asymptomatic
- Decision to treat is based on the severity of symptoms.



CT에서 우연히 발견된 게실, F/54



Esophageal dysphagia


- Structural dysphagia
 - oversized bolus or a narrow lumen
- Motor dysphagia
 - abnormalities of peristalsis or impaired sphincter relaxation after swallowing

Structural esophageal dysphagia

- Solid food dysphagia **when narrowed to <13 mm**
 - Also with larger diameters in the setting of poorly masticated food or motor dysfunction
 - Circumferential lesions: more likely to cause
- Common causes: masses (both intrinsic and extrinsic), stricture (peptic, RT, op, EoE), rings, webs


Esophageal cancer

- Progressive over weeks to months
- From solid to liquid
- Weight loss
- Risk factors





Peptic stricture

- A prolonged history of heartburn/regurgitation



RT-induced esophageal stricture



Motor dysphagia


- Diseases affecting smooth muscle involve the esophageal body and/or and the LES.
- Constant (or intermittent) dysphagia with both liquids and solids
- Common causes: achalasia, esophageal spasm, systemic sclerosis, EoE

Symptoms of achalasia

1. Dysphagia for **solids and liquids** (>90%)
2. Regurgitation of undigested food (76-91%)
3. Weight loss (35-91%)
4. Chest pain (25-64%)
5. Heartburn (18-52%)
6. Nocturnal cough (30%)

→ Often diagnosed as refractory GERD

Diagnosis of achalasia



Eosinophilic esophagitis (EoE)





Figure 2. Histologic Characteristics of Eosinophilic Esophagitis.

Routine staining with hematoxylin and eosin reveals numerous eosinophils (thin arrows), dilated intercellular spaces (thick arrow), basal zone hyperplasia (circle), and papillary elongation (bracket).





Table 1. Medical Treatment of Active Eosinophilic Esophagitis.

Method	Specific Recommendation or Dosage
Elemental diet therapy	—
Elimination diet therapy	
Six-food elimination	Elimination of milk, wheat, eggs, soy, seafood, and nuts
Four-food elimination	Elimination of milk, wheat, eggs, and soy
Allergy testing–based	Elimination of foods on the basis of results of radioallergosorbent testing, skin-prick testing, or atopy-patch testing*
Omeprazole (proton-pump inhibitor)†	Children with body weight 10 to 20 kg: 10 mg twice a day Children with body weight >20 kg: 20 mg twice a day Adults: 40 mg once or twice a day
Glucocorticoids	
Fluticasone	Children: 220 to 440 µg twice a day Adults: 440 to 880 µg twice a day
Budesonide	Children: 0.25 to 0.5 mg twice a day Adults: 1 to 2 mg twice a day

* Approximately 45% of patients have a sustained response to this type of diet therapy.⁶⁸

† An equivalent proton-pump inhibitor can be administered.

Asymptomatic EoE, M/70





Asia-Pacific consensus on the management of gastroesophageal reflux disease: Update

Kwong Ming Fock,^{*} Nicholas J Talley,[†] Ronnie Fass,[‡] Khean Lee Goh,[§] Peter Katelaris,[¶] Richard Hunt,^{**} Michio Hongo,^{††} Tiing Leong Ang,^{*} Gerald Holtmann,^{‡‡} Sanjay Nandurkar,^{§§} San Ren Lin,^{¶¶} Benjamin CY Wong,^{***} Francis KL Chan,^{†††} Abdul Aziz Rani,^{‡‡‡} Young-Tae Bak,^{§§§} Jose Sollano,^{¶¶¶} Lawrence KY Ho^{****} and Sathoporn Manatsathit^{††††}

- **Statement 1:** GERD is defined as a disorder in which gastric contents reflux recurrently into the esophagus, causing troublesome symptoms and/or complications.
- **Statement 2:** Typical symptoms of reflux are **heartburn** (retrosternal burning sensation) and **acid regurgitation**, which are commonly experienced by Asian patients.

Rumination syndrome




- Effortless, often repetitive, regurgitation of recently ingested food into the mouth (in humans)
- Not preceded by nausea or retching
- May be *erroneously* considered to have **gastroparesis** or **GERD**

Treatment for rumination syndrome


- The mainstay of treatment
 - explanation of the condition and mechanism
 - behavioural modifications
- Diaphragmatic breathing during the postprandial period
 - disappearance of rumination in 30–66% and improvement in another 20–55%
- Chewing gum
 - reduces the number of rumination events in young children and adolescents


PPI efficacy for potential manifestations of GERD

Estimates based on available RCT data



Refractory GERD management





Odynophagia

- Pain upon swallowing
- Strongly suggests the mucosal injury
- Causes: pill-induced esophagitis or infectious esophagitis, peptic esophagitis, RT-induced esophagitis

Esophageal candidiasis

- Presentation: Odynophagia with dysphagia
 - May be an incidental finding
- Treatment for symptomatic and/or immunocompromised patients
 - Fluconazole 100 mg/day for 7-14 days

Antifungal treatment is not associated with remission for asymptomatic esophageal candidiasis: observational study (N=142)

TABLE 4. Univariate and Multivariate Analyses of Predisposing Factors for Nonremission of Esophageal Candidiasis

Variables	Univariate Analysis		Multivariate Analysis	
	OR (95% CI)	P Value	OR (95% CI)	P Value
Age (years)	1.052 (1.009–1.098)	0.019	1.031 (0.978–1.087)	0.258
Sex				
Female	1		1	
Male	0.905 (0.375–2.186)	0.825	0.752 (0.250–2.259)	0.612
Diabetes	0.172 (0.022–1.345)	0.093	0.247 (0.029–2.117)	0.202
Cardiovascular disease	8.074 (1.405–46.412)	0.019	5.661 (0.785–40.831)	0.085
Steroid use	3.857 (0.738–20.152)	0.110	2.649 (0.313–22.443)	0.372
History of pulmonary tuberculosis	6.183 (1.807–21.159)	0.004	4.495 (1.023–19.762)	0.047
Triglyceride (mg/dL)	0.995 (0.988–1.002)	0.157	0.994 (0.985–1.003)	0.165
Rheumatoid factor (IU/mL)	1.071 (0.981–1.169)	0.127	1.031 (0.945–1.124)	0.490
Esophageal Candidiasis Grade				
I	1		1	
II	1.539 (0.671–3.533)	0.309	1.164 (0.423–3.200)	0.768
III	9.000 (0.768–105.430)	0.080	6.932 (0.469–102.427)	0.159
Antifungal treatment	0.743 (0.313–1.762)	0.500	0.682 (0.238–1.950)	0.475

Details of antifungal treatment in the real practice

TABLE 3. Comparison of Antifungal Treatment Between Remission and Nonremission Group

Variables	Remission (n = 111)	Nonremission (n = 31)	P Value
Antifungal treatment	82 (73.9)	21 (67.7)	0.499
Antifungal agent			0.467
Fluconazole	69 (84.1)	20 (95.2)	
Itraconazole	3 (3.7)	0 (0)	
Nystatin	3 (3.7)	1 (4.8)	
Unknown	7 (8.5)	0 (0)	
Treatment duration (days)*	9.0 ± 2.8	10.2 ± 3.1	0.099
Treatment duration categories*			0.090
≤7 days	32 (46.4)	8 (40.0)	
>7 and <14 days	28 (40.6)	5 (25.0)	
≥14 days	9 (13.0)	7 (35.0)	
Daily dose (mg)*	106.5 ± 35.3	107.5 ± 33.5	0.912
Total dose (mg)*	973.9 ± 443.1	1075.0 ± 408.3	0.363
Total dose categories*			0.438
≤700 mg	28 (40.6)	5 (25.0)	
>700 and <1400 mg	18 (26.1)	7 (35.0)	
≥1400 mg	23 (33.3)	8 (40.0)	

Data are shown as the mean ± SD or number (%) of patients.

* Subgroup analysis was performed in a group of patients who received fluconazole.

Chest pain

Noncardiac chest pain (NCCP)

- Retrosternal pain by esophageal pathology
- Sensory innervation of intrathoracic organ is intertwined.
- Pain upon exertion vs during and/or after meals
 - lack of accuracy in making a diagnosis

Prevalence of RE in NCCP

- A retrospective study (N=217)





Fig. 2. Prevalence of reflux esophagitis in patients with noncardiac chest pain. Among them, 68 patients (31.3%) in minimal change esophagitis; 26 patients (12.0%) in Los Angeles (LA) grade A; 2 patients (0.9%) in LA grade B. There were no patients with severe erosive esophagitis.


Upper GI evaluation in NCCP

- A prospective analysis in 58 NCCP patients



'식도염이 심하다', 76/F




NSTEMI → PCI



Globus

- Non-painful sensation of 'lump' in the throat
- Usually in the region of the sternal notch
- Experienced without swallowing
- May actually get better with swallowing


Rt tonsillar cancer with neck meta



Potential causes of globus

- **Gastroesophageal reflux disease**
- Abnormal upper esophageal sphincter function
- Esophageal motor disorders
- Pharyngeal inflammatory causes
- Upper aerodigestive malignancy
- Hypertrophy of the base of the tongue
- Retroverted epiglottis
- Thyroid diseases
- Cervical heterotopic gastric mucosa
- Rare laryngopharyngeal tumors
- **Psychological factors and stress**

Approach for patients with globus



Supraesophageal symptoms (=extraesophageal symptoms)

- Recognition of the relationship of GERD with several pulmonary and otolaryngologic problems like cough, hoarseness, and asthma
- Weaker association than previously noticed

No effect of PPI on poorly controlled asthma

- A parallel-group, double-blind trial (N=412)



Variable	Placebo (N = 193)	Esomeprazole (N = 200)	Incidence- Rate Ratio, Esomeprazole vs. Placebo (95% CI)	P Value	
				Esomeprazole vs. Placebo†	Gastroesophageal- Reflux Interaction‡
Asthma episodes, according to definition that did not include use of beta-agonists as a criterion					
No. of events	201	224			
No. of events/person-yr	2.3	2.5	1.1 (0.8–1.5)	0.66	0.93
Patients with ≥1 event (%)	42	42			

† P values are for the treatment effect of esomeprazole as compared with placebo.

‡ P values are for the modification of the treatment effect by pH-monitoring results, as estimated by linear regression.

Extra-esophageal symptoms

- in Korean GERD patients (N=1,712)



Overdiagnosis of GERD as the sole cause of a patient's complaints

